Sculptor Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Sculptor Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,000	Closed	-$495K	–	728
2022 Q4	$495K	Hold	40,000	–	–	0.01%	438
2022 Q3	$558K	Hold	40,000	–	–	0.01%	619
2022 Q2	$552K	Hold	40,000	–	–	0.01%	661
2022 Q1	$651K	Buy	+40,000	New	+$627K	0.01%	725
2017 Q4	–	Sell	-182,700	Closed	-$10.6M	–	210
2017 Q3	$10.6M	Buy	+182,700	New	+$19.7M	0.05%	118

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Sculptor Capital's ICPT Position: Q1 2023 in Review

Sculptor Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 40,000 shares — an estimated $495K sold.

Sculptor Capital first reported a position in ICPT in Q3 2017 and held it in 5 quarters. The position peaked at $10.6M in Q3 2017. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

Sculptor Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 40,000 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $495K.
Sculptor Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
Sculptor Capital's Intercept Pharmaceuticals, Inc. position peaked at $10.6M in Q3 2017.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.